FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,788 | -64.3% | 5,089 | -19.8% | 0.00% | – |
| Q2 2023 | $30,257 | -18.9% | 6,345 | -3.3% | 0.00% | – |
| Q1 2023 | $37,320 | -40.9% | 6,564 | +3.0% | 0.00% | – |
| Q4 2022 | $63,153 | +187.1% | 6,371 | +520.4% | 0.00% | – |
| Q3 2022 | $22,000 | +10.0% | 1,027 | +26.6% | 0.00% | – |
| Q2 2022 | $20,000 | -95.0% | 811 | -20.1% | 0.00% | -100.0% |
| Q1 2022 | $401,000 | +557.4% | 1,015 | +0.3% | 0.00% | – |
| Q4 2021 | $61,000 | -35.1% | 1,012 | -35.8% | 0.00% | – |
| Q3 2021 | $94,000 | -70.6% | 1,577 | -57.0% | 0.00% | -100.0% |
| Q2 2021 | $320,000 | +267.8% | 3,669 | +249.4% | 0.00% | – |
| Q1 2021 | $87,000 | -44.9% | 1,050 | -39.2% | 0.00% | – |
| Q4 2020 | $158,000 | -19.8% | 1,726 | -68.1% | 0.00% | -100.0% |
| Q3 2020 | $197,000 | +16.6% | 5,418 | +9.8% | 0.00% | 0.0% |
| Q2 2020 | $169,000 | +44.4% | 4,934 | +1.5% | 0.00% | – |
| Q1 2020 | $117,000 | – | 4,863 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |